Localized Prostate Cancer x Dr. Charles Ryan 2025 UPDATE

Dr. Charles Ryan, a leading GU oncologist at Memorial Sloan Kettering, discusses the latest in localized prostate cancer. He highlights the declining PSA screening rates and their impact on diagnosis. The conversation touches on key risk factors like age and genetics, and advances in diagnostics, including genomic data. Hormone therapy's role and patient management strategies are also examined. Additionally, he addresses biochemical recurrence post-treatment and the promising results of recent trials like EMBARK, emphasizing the evolving landscape of prostate cancer care.